Biomarker & Intervention Discovery
Non-Hodgkin Lymphoma (NHL)
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
NIH funding$281MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionIndolent NHL (follicular): spontaneous remission in 20-30% of early-stage, allowing watch-and-wait; aggressive NHL…
Best-intervention remissionDLBCL with R-CHOP: 60-70% cure rate; Pola-R-CHP (polatuzumab): 27% improvement in 2-year PFS (POLARIX); DLBCL…
Gap sizeVariable by subtype; DLBCL has genuinely curative potential; indolent NHL remains manageable but generally incurable…
Primary barrieraccess (CAR-T) + biological (indolent NHL)
Full remission profile →
Remission & chronicity
Spontaneous remission
Indolent NHL (follicular): spontaneous remission in 20-30% of early-stage, allowing watch-and-wait; aggressive NHL (DLBCL): rapidly lethal without treatment in weeks-months
Best-intervention remission
DLBCL with R-CHOP: 60-70% cure rate; Pola-R-CHP (polatuzumab): 27% improvement in 2-year PFS (POLARIX); DLBCL relapsed: axicabtagene ciloleucel (axi-cel) CAR-T: 40-50% long-term remission; follicular lymphoma: obinutuzumab + chemotherapy 85-90% response, durable
Gap size
Variable by subtype; DLBCL has genuinely curative potential; indolent NHL remains manageable but generally incurable with current therapy
Primary barrier
access (CAR-T) + biological (indolent NHL)
CAR-T therapy is transformative in relapsed DLBCL but manufacturing time (2-3 weeks), cost ($400K+), and centre requirements limit access; bispecific antibodies (epcoritamab, glofitamab) offer off-the-shelf alternative
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Non-Hodgkin Lymphoma (NHL)” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."